DRUG CANDIDATES


ICA-105665

Our most advanced compound for the treatment of epilepsy and neuropathic pain is

ICA- 105665, for which we are currently conducting a multiple dose escalation study in healthy male  volunteers and a cohort of epilepsy patients who are currently well controlled on other anticonvulsant medications. In addition, we have identified  several lead compounds that also target  specific potassium channels, which are located primarily on the

                                                                      membrane of nerve cells, or  neurons, present

                                                                      in particular regions of the  central and

                                                                      peripheral nervous system. We

                                                                      have retained all worldwide rights to these 

                                                                      compounds. 

 

 

   Senicapoc for Asthma

  Senicapoc is a novel small molecule  

  potassium channel inhibitor that we are

  developing for the treatment of asthma, for

  which we recently completed Phase I clinical

  studies. The company expects to initiate a

  Phase II clinical trial in patients with

  allergen- induced asthma at selected sites in

  the UK during the fall of 2008.  Senicapoc

                                                                          targets a particular  potassium channel that

                                                                          is expressed on a  number of cells believed

                                                                          to be important in the pathogenesis of

                                                                          asthma, including various cells of the

                                                                          immune and inflammatory system and airway

                                                                          epithelial cells. Senicapoc is taken orally and

                                                                          is being developed for once-a-day dosing.

                                                                          We retain all worldwide rights to senicapoc.

Next: Research Programs





 Contact Us     Directions      Site Map Copyright © Icagen, Inc.   All rights reserved